Search

Corvus Pharmaceuticals Inc

Gesloten

14.28 -0.14

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.03

Max

15.03

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+112.08% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-29M

1.3B

Vorige openingsprijs

14.42

Vorige sluitingsprijs

14.28

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 jul 2026, 23:56 UTC

AAR Corp shares are trading higher in after-market hours, reflecting typical fluctuations around the midpoint of their one-month range.

20 jul 2026, 23:56 UTC

Nucor Corp shares are higher in after-market trading, reflecting routine performance. No specific news was identified to explain the price movement.

20 jul 2026, 23:56 UTC

Epam Systems Inc. shares declined in after-market trading, aligning with a broader economic backdrop following a slight decrease in the Conference Board's leading economic index.

20 jul 2026, 23:56 UTC

Definitive Healthcare Corp shares are lower in after-market hours, continuing a trend from recent sessions amid broader market uncertainties and weak economic data.

20 jul 2026, 23:56 UTC

News

Brookdale Senior Living announced its second-quarter 2026 earnings release dates, boosting investor sentiment. Shares are trading higher in after-market hours.

20 jul 2026, 23:56 UTC

Delek US Holdings Inc shares are higher in after-market hours, continuing a directional advance from earlier in the session. No specific news was identified.

20 jul 2026, 23:56 UTC

Harley-Davidson Inc shares are higher in after-market trading, recovering from an earlier dip and positioning above the 20-day moving average.

20 jul 2026, 23:56 UTC

News

Valero Energy Corp gains in after-market trading on strong earnings forecast, with projected EPS of $9.81 and revenue expectations of $35.95 billion.

20 jul 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

20 jul 2026, 23:56 UTC

Correlated Moves

Teradyne Inc shares are higher in after-market trading, recovering from earlier session lows, as the Nasdaq 100 Index also moves up.

20 jul 2026, 23:56 UTC

NextDecade Corp. shows a slight uptick in after-market trading, remaining stable around the midpoint of its one-month trading range.

20 jul 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

20 jul 2026, 23:56 UTC

Marathon Petroleum shares are higher in after-market trading, maintaining strength above the 20-day moving average despite a decline in the leading economic index.

20 jul 2026, 23:56 UTC

Salesforce Inc. shares remained roughly flat after market hours. The Conference Board reported a modest decline in its leading economic index for June.

20 jul 2026, 23:56 UTC

Aurora Innovation Inc shares are lower in after-market hours, with no specific news identified. Broader economic concerns include a decline in the leading economic index.

20 jul 2026, 23:51 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Emerging Markets ETF rises in after-market trading, supported by strong performances from Taiwan Semiconductor and HDFC Bank, despite remaining near recent lows.

20 jul 2026, 23:51 UTC

Sabre Corp shares are lower in after-market hours, continuing a decline since Monday's close and remaining below their 20-day moving average.

20 jul 2026, 23:51 UTC

Daktronics Inc shares are higher in after-market hours, reflecting strong momentum and trading near the upper end of their one-month range.

20 jul 2026, 23:51 UTC

Reinsurance Group of America shares are higher in after-market hours, supported by a significant rise in the reinsurance sub-sector. The price is near its one-month high.

20 jul 2026, 23:51 UTC

CenterPoint Energy Inc shares are higher in after-market trading, reflecting a steady upward movement since Monday's close amid rising Treasury yields and economic index concerns.

20 jul 2026, 23:51 UTC

Geo Group Inc shares are lower in after-market hours, reflecting broader market concerns over rising Treasury yields and a decline in the leading economic index.

20 jul 2026, 23:51 UTC

HealthStream Inc shares are lower in after-market trading. Broader market concerns include rising Treasury yields and a decline in the Conference Board's leading economic index.

20 jul 2026, 23:51 UTC

CEVA Inc shares rose in after-market trading, recovering from earlier volatility and contrasting with four consecutive lower closes. The stock remains below its 20-day moving average.

20 jul 2026, 23:51 UTC

News
Correlated Moves

Ally Financial shares are lower in after-market trading despite the board declaring a quarterly cash dividend of $0.30 per share.

20 jul 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, with no specific news identified to explain the movement. Trading activity has been notably active.

20 jul 2026, 23:51 UTC

Amkor Technology Inc shares are trading higher in after-market hours, despite no specific news and increased caution in the broader market.

20 jul 2026, 23:51 UTC

Mexico's Upcoming Balance of Trade Data on July 27, 2026, Expected to Reflect Economic Health Amid Geopolitical Tensions and Investment Recovery Signals.

20 jul 2026, 23:51 UTC

Australia's Full-Time Employment Change Report Set for July 23, 2026: Market Eyes Job Growth Amid Economic Uncertainty.

20 jul 2026, 23:51 UTC

Australia's July 2026 employment change forecast predicts a modest increase of 15,000 jobs amid mixed labor market sentiment and potential impacts from skilled migration reforms.

20 jul 2026, 23:51 UTC

Australia's unemployment rate for June 2026 is set to be released on July 23, with a forecast of 4.4%, amid cautious optimism in local markets despite global economic uncertainties.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

112.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  112.08%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat